← All causality assessments
Causality: well established
Causality assessment · Causality: well established
Gentamicin Sulfate and Renal Failure: is the FAERS signal real?
A written Bradford Hill assessment of one drug–event pair. The grade is a judgement about the signal, not a statement that this drug causes this event in any one person; FAERS counts are reports, not rates.
Gentamicin Sulfate ↔ Renal Failure
n=705 co-reports · PRR 7.1 · ROR 7.4
Idarubicin is an anthracycline chemotherapy agent. Myelosuppression is the expected on-target toxicity: DNA intercalation and topoisomerase II inhibition kill dividing bone marrow cells. 2,105 co-reports (PRR 16.0) reflect real myelotoxicity. The label carries a boxed warning for myelosuppression.
Boxed warning: idarubicin label (myelosuppression). Anthracycline literature.
| Bradford Hill viewpoint | Status | Note |
|---|---|---|
| Temporality (necessary) | met | Documented in label |
| Strength | met | PRR 16.0 with 2,105 co-reports |
| Consistency | met | Reproduced across anthracycline class |
| Specificity | partial | Specific to DNA-intercalating agents |
| Biological gradient | met | Correlates with cumulative dose |
| Plausibility | met | Known bone marrow toxicity mechanism |
| Coherence | met | Coherent with chemotherapy pharmacology |
| Experiment | met | Multiple RCTs confirm |
| Analogy | met | Other anthracyclines produce same effect |
This table is this page's own qualitative read of the literature cited above, not an automated or citation-gated assessment — see the note at the bottom of this page.
✗ No ClinicalTrials.gov results-posting trial in the top search hits for Gentamicin captured renal failure as a tracked adverse event in a usable structure. Myelosuppression is a standard haematological endpoint in all chemotherapy registration trials.